Pharma, FDA Got A Bum Rap On Post-Market Studies, Booz Allen Report Says

Nearly 20 percent of post-marketing studies tagged in the agency's database as open had actually been fulfilled or released, according to the backlog review.

More from Archive

More from Pink Sheet